Attached files

file filename
EX-99.1 - PRESS RELEASE - TENAX THERAPEUTICS, INC.oxbt_ex991.htm
EX-99.2 - CONFERENCE CALL TRANSCRIPT - TENAX THERAPEUTICS, INC.oxbt_ex992.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2014

Oxygen Biotherapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-34600
 
26-2593535
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)

ONE Copley Parkway, Suite 490
Morrisville, NC 27560
(Address of principal executive offices) (Zip Code)

919-855-2100
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 
 
 
 
Item 2.02                      Results of Operations and Financial Condition.
 
On July 29, 2014, Oxygen Biotherapeutics, Inc. (the “Company”) issued a press release to report its operating results for the fourth quarter and fiscal year ended April 30, 2014. The release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
 
Also on July 29, 2014, following the issuance of the press release referred to above, the Company conducted a conference call to discuss the financial results for the fourth quarter and fiscal year ended April 30, 2014. A copy of the transcript of the conference call is furnished herewith as Exhibit 99.2 and incorporated herein by reference.
 
The information in this Item 2.02, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01                      Financial Statements and Exhibits

(d)           Exhibits

Exhibit No.
 
Description
     
Exhibit 99.1
 
Press release dated July 29, 2014.
     
Exhibit 99.2
 
Conference call transcript dated July 29, 2014.

 
2

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
Oxygen Biotherapeutics, Inc.
 
       
Date: July 30, 2014
By:
/s/ Michael B. Jebsen  
   
Michael B. Jebsen
 
   
Chief Financial Officer
 
       
 

 
 
3

 
 
Exhibit Index
 
Exhibit No.
 
Description
     
Exhibit 99.1
 
Press release dated July 29, 2014.
     
Exhibit 99.2
 
Conference call transcript dated July 29, 2014.
 
 
 
 
 
4